{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:57:30Z","timestamp":1786679850842,"version":"build-2736575974"},"reference-count":111,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.103720","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:39:47Z","timestamp":1775666387000},"page":"103720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2814-1644","authenticated-orcid":false,"given":"Francoise Galateau","family":"Sall\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103720_bib1","series-title":"Thoracic Tumours","year":"2021"},{"key":"10.1016\/j.jtho.2026.103720_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2026.103720_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/modpathol.2012.39","article-title":"Pleomorphic mesothelioma: report of 10 cases","volume":"25","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41379-021-00900-z","article-title":"Molecular characterization of pleomorphic mesothelioma: a multi-institutional study","volume":"35","author":"Roy","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103720_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103720_bib8","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib10","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.3390\/ijms21124327","article-title":"Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review","volume":"21","author":"Panou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2026.103720_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405231121","article-title":"Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling","volume":"121","author":"Novelli","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.103720_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103720_bib13","article-title":"The predictive and prognostic nature of programmed death-ligand 1 in malignant pleural mesothelioma: a systematic literature review","volume":"3","author":"Mansfield","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103720_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2026.103720_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jtho.2022.07.1150","article-title":"There is an unmet need for another programmed cell death protein 1\/programmed death-ligand 1 inhibitor","volume":"17","author":"Feng","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10147-025-02706-4","article-title":"Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data","volume":"30","author":"Kanayama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2024.01.017","article-title":"Immunotherapy is a good standard option for patients with malignant pleural mesothelioma, despite the real-world results from Australia","volume":"19","author":"Smesseim","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","article-title":"Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center","volume":"15","author":"Galateau Salle","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/jclinpath-2016-203993","article-title":"Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma","volume":"70","author":"Alchami","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/his.15106","article-title":"Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"84","author":"Klebe","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2026.103720_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ajcp\/aqab054","article-title":"Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection in pleural malignant mesothelioma: an international multi-institutional analysis","volume":"156","author":"Schulte","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group","volume":"148","author":"Husain","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.103720_bib30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/PAS.0000000000001469","article-title":"HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma","volume":"44","author":"Naso","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/his.14783","article-title":"Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases","volume":"82","author":"Churg","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2026.103720_bib32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cncy.22326","article-title":"Testing for BAP1 loss and CDKN2A\/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology","volume":"128","author":"Chevrier","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2026.103720_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jasc.2020.05.015","article-title":"The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management","volume":"9","author":"Pinto","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jtho.2026.103720_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jasc.2024.03.001","article-title":"Application of the newly published International System for Reporting serous Fluid Cytopathology in atypical and suspicious diagnosis: a four-year retrospective analysis","volume":"13","author":"Shen","year":"2024","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jtho.2026.103720_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.103720_bib36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100036","article-title":"Immunohistochemical demonstration of Merlin\/NF2 loss in mesothelioma","volume":"36","author":"Martin","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cncy.22409","article-title":"Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma","volume":"129","author":"Kinoshita","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2026.103720_bib39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103720_bib40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103720_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2026.103720_bib42","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2026.103720_bib43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41388-022-02577-3","article-title":"BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms","volume":"42","author":"Singh","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2026.103720_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib46","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtho.2023.05.028","article-title":"The role of germline mutations in thoracic malignancies: between myth and reality","volume":"18","author":"Farinea","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib47","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2026.103720_bib48","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.5858\/arpa.2023-0213-RA","article-title":"Molecular and immunohistochemical testing in mesothelioma and other mesothelial lesions","volume":"148","author":"Hung","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.103720_bib49","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib50","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2589-7500(21)00104-7","article-title":"The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study","volume":"3","author":"Zauderer","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jtho.2026.103720_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","article-title":"Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis","volume":"146","author":"Cantini","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib52","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2026.103720_bib54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jtho.2023.11.017","article-title":"The interplay between the immune system, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy","volume":"19","author":"Nel","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103681","article-title":"The International Association for the Study of Lung Cancer pleural mesothelioma staging project: impact of common molecular alterations and PD-L1 expression on overall survival in a select cohort from the IASLC 9th edition staging database","author":"Yang","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib56","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib57","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","article-title":"Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations","volume":"20","author":"Carbone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2021-0331-OA","article-title":"A combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A fluorescence in situ hybridization in diagnosis and prognosis of pleural mesotheliomas","volume":"147","author":"Brcic","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2026.103720_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib60","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtho.2026.103720_bib61","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1158\/0008-5472.CAN-18-0814","article-title":"Specific targeting of MTAP-deleted tumors with a combination of 2-fluoroadenine and 5-methlthioadenosine","volume":"78","author":"Tang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103720_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","article-title":"NF2 alteration in mesothelioma","volume":"5","author":"Sekido","year":"2023","journal-title":"Front Toxicol"},{"key":"10.1016\/j.jtho.2026.103720_bib63","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103720_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0681","article-title":"A novel irreversible TEAD inhibitor, SWTX-143, blocks hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models","volume":"23","author":"Hillen","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103720_bib65","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-24-0085","article-title":"Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features","volume":"30","author":"Yang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103720_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41379-021-00920-9","article-title":"Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status","volume":"35","author":"Naso","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib67","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/genes6030500","article-title":"Hedgehog signaling in malignant pleural mesothelioma","volume":"6","author":"Felley-Bosco","year":"2015","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jtho.2026.103720_bib68","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","article-title":"Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo by affecting stroma","volume":"15","author":"Meerang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103720_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable response to vismodegib in PTCH1 F1147fs mutant relapsed malignant pleural mesothelioma: implications for mesothelioma drug treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/gcc.23119","article-title":"Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features","volume":"62","author":"Michal","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib72","article-title":"Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma","volume":"5","author":"Parikh","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103720_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29544","article-title":"Mesothelioma with ALK gene mutations in two pediatric patients: clinical course and outcome","volume":"69","author":"Kimpo","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib74","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/PAS.0000000000000864","article-title":"A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib75","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/10935266211021222","article-title":"Malignant mesothelioma with EWSR1-ATF1 fusion in two adolescent male patients","volume":"24","author":"Ren","year":"2021","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib76","article-title":"Malignant peritoneal mesothelioma with EWSR1-ATF1 fusion: a case report","volume":"2","author":"Ke","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103720_bib77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/gcc.23074","article-title":"EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: report of 3 cases in support of an emerging entity","volume":"61","author":"Dermawan","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib78","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/gcc.23118","article-title":"NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid\/microcystic morphology","volume":"62","author":"Agaimy","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103644","article-title":"Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms","volume":"9","author":"Benzerdjeb","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.103720_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98414-w","article-title":"Integrated genomics point to immune vulnerabilities in pleural mesothelioma","volume":"11","author":"Nastase","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2026.103720_bib81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2026.103720_bib83","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.3390\/cancers14246063","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"14","author":"Gemelli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.103720_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103639","article-title":"A systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma","volume":"172","author":"Tagliamento","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2026.103720_bib85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1148\/radiol.2412051020","article-title":"Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy","volume":"241","author":"Agarwal","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2026.103720_bib86","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1440-1843.2011.01973.x","article-title":"Pleural controversy: close needle pleural biopsy or thoracoscopy-which first?","volume":"16","author":"Koegelenberg","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.jtho.2026.103720_bib87","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103720_bib88","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1378\/chest.09-0884","article-title":"Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial","volume":"137","author":"Metintas","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2026.103720_bib89","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.chest.2024.03.038","article-title":"Image-ass\u0131sted pleural needle biopsy or medical thoracoscopy: which method for which patient? - a random\u0131zed controlled trial","volume":"166","author":"Metintas","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2026.103720_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/PAP.0000000000000180","article-title":"Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples","volume":"25","author":"Monaco","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.jtho.2026.103720_bib91","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1002\/cncr.32416","article-title":"Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma","volume":"125","author":"Chirieac","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib92","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2019.06.020","article-title":"Pathologic considerations and standardization in mesothelioma clinical trials","volume":"14","author":"Tsao","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib93","article-title":"Perioperative discordance in mesothelioma cell type after pleurectomy\/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?","volume":"37","author":"Ventura","year":"2023","journal-title":"Interdiscip CardioVasc Thorac Surg"},{"key":"10.1016\/j.jtho.2026.103720_bib94","series-title":"World Cancer Report: Cancer Research for Cancer Prevention Epigenetics Potential in Diagnostics, Therapy and Prevention","year":"2020"},{"key":"10.1016\/j.jtho.2026.103720_bib95","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jtho.2021.05.015","article-title":"DNA methylation as a diagnostic biomarker for malignant mesothelioma: a systematic review and meta-analysis","volume":"16","author":"Vandenhoeck","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib96","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jmoldx.2021.04.002","article-title":"DNA methylation profiling discriminates between malignant pleural mesothelioma and neoplastic or reactive histologic mimics","volume":"23","author":"Bertero","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jtho.2026.103720_bib97","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jtho.2025.07.132","article-title":"Prospective analysis of mesotheliomas in subjects with BAP1 cancer syndrome: clinical characteristics and epigenetic correlates of disease","volume":"20","author":"Wu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2022.06.008","article-title":"DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas","volume":"170","author":"Jurmeister","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib99","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib100","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib101","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.103720_bib102","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103720_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","article-title":"Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients","volume":"124","author":"Hylebos","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib104","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ijc.34339","article-title":"Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: the EPIC prospective cohort","volume":"152","author":"Allione","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41586-024-07894-z","article-title":"A pathology foundation model for cancer diagnosis and prognosis prediction","volume":"634","author":"Wang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103720_bib106","article-title":"MesoGraph: automatic profiling of mesothelioma subtypes from histological images","volume":"4","author":"Eastwood","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2026.103720_bib107","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103720_bib108","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-022-00388-9","article-title":"Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer","volume":"3","author":"Boehm","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2026.103720_bib109","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103720_bib110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103720_bib111","article-title":"A molecular phenotypic map of malignant pleural mesothelioma","volume":"12","author":"Di Genova","year":"2022","journal-title":"GigaScience"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:40:06Z","timestamp":1783071606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556086426001735"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103720","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103720"}}